Standard Biotools Inc. · NASDAQ:LAB
Standard Biotools — Fluidigm — Merger or Acquisition (February 2022)
21 slides from Standard Biotools's merger presentation, Feb 14, 2022
Slide 1: Strategic Capital Infusion Overview
Strategic Capital Infusion Overview February 2022
Slide 2: Legal Information: Forward-looking Statements
Legal Information Forward-looking Statements variations in customer operations; unanticipated increases in costs or expenses; uncertainties in contractual relationships; reductions in research and development spending or changes in This presentation and the accompanying oral presentation contain for
Slide 3: Legal Information (contd.): Additional Information and Where to Find It
Legal Information (contd.) Additional Information and Where to Find It Fluidigm, its directors and certain executive officers are participants in the solicitation of proxies the Transaction at the SEC’s website (http://www.sec.gov). Copies of Fluidigm’s definitive from shareholders in connection wit
Slide 4: Strategic Capital and Leadership to Reinvigorate Growth
Strategic Capital and Leadership to Reinvigorate Growth A New Chapter of Focused Execution, Cost Structure Optimization and High Growth Initiatives Transformative Capital from Leading Life Sciences Investors $250 million investment to reinvigorate growth through optimization of Mass Cytometry and Mi
Slide 5: Transaction Details
Transaction Details • $225 million zero coupon convertible preferred shares Investment • $25 million bridge financing at varying PIK interest rates (10% through February, 12% through May, 14% through August and 16% thereafter until maturity on September 30, 2025) – Already funded Amount ‒ Automatica
Slide 6: Strategic Rationale
Strategic Rationale Upon closing, the $250 million of new capital will fuel the realization of identified organic growth and cost opportunities and enable management to pursue new growth vectors in complementary technologies Accelerate Growth in Mass Cytometry P Focus Microfluidics Business Toward P
Slide 7: Unanimous Support from the Fluidigm Board of Directors
Unanimous Support from the Fluidigm Board of Directors The Fluidigm Board of Directors conducted a comprehensive review to evaluate Fluidigm’s strategic options to maximize value for its shareholders. The Fluidigm Board of Directors believes that this strategic capital infusion from Casdin and Vikin
Slide 8: Accelerate Growth in Mass Cytometry
Accelerate Growth in Mass Cytometry Accelerating Mass Cytometry Suspension Mass Cytometry • Invest in direct sales and marketing to expand relationships deeper into the life science ecosystem with a particular focus on biopharma, • Expand CyTOF and IMC platforms to diagnostics and the broader CRO an
Slide 9: Focus Microfluidics Business Toward Profitable Growth
Focus Microfluidics Business Toward Profitable Growth Opportunities in Microfluidics Highly Targeted Growth in Microfluidics • Focus on targeted end-applications • Stabilize the base microfluidics business with the (e.g., proteomics, biomarker analysis) disciplined launch of the Biomark X platform a
Slide 10: Expand Offering Through Complementary M&A
Expand Offering Through Complementary M&A Expand Offering to Meet Needs of Researchers Greater Breadth and Scale Proprietary deal flow through relationships cultivated over decades • Researchers are dependent on a wide variety of technologies that are most Target de-risked technologies with immediat
Slide 11: Optimize the Cost Structure
Optimize the Cost Structure Management Team with Deep Experience in Clear Path to Sustainable Production Methodology Focused on Eliminating Positive Cash Flow Waste and Enhancing Quality Principles • Focus on cost structure optimization Deploy best in class production methodology focused on eliminat
Slide 12: Enhance Management and the Board of Directors
Enhance Management and the Board of Directors Adding industry experts with deep experience and relationships to drive the company’s strategy Dr. Michael Egholm Alex Kim Alex Arfaei Eli Casdin Dr. Martin Madaus President, CEO and Director COO Senior Vice President, Director Director Corporate Develop
Slide 13: Proceeds of the $250 Million Capital Infusion Expected Uses
The Proceeds of the $250 Million Capital Infusion Are Expected to be Used for Transaction Expenses, Working Capital and Potential Future M&A, Potentially Including: 1 Accelerating growth in Mass Cytometry 2 Achieving significantly greater breadth and scale 3 Leveraging a larger menu to expanding cus
Slide 14: Leveraging Strong Technology Foundation to Create Industry Leader
Leveraging Strong Technology Foundation to Create Industry Leader Today Strategy Future • Strong underlying technology • Accelerated growth • Invest in Mass Cytometry in Mass Cytometry and • New name reflects vision of • Optimize cost structure Microfluidics becoming an essential • Enhance portfolio
Slide 15: Fluidigm Overview
Fluidigm Overview Harnessing the Power of CyTOF® and Microfluidics Technologies 15
Slide 16: Drive Meaningful Insight in Health and Disease to Improve Life
Drive Meaningful Insight in Health and Disease to Improve Life Advance human health Reveal, understand and by deploying address the biological innovative technologies. complexities of disease. 16
Slide 17: Leading Provider of Indispensable Tools and Consumables
Leading Provider of Indispensable Tools and Consumables $ $ % 38.0M - 38.3M ~13-14 Manufacturing Headquarters South San Francisco, Q4 preliminary revenue Q4 base product and service Singapore | Ontario, Canada | CA, USA preliminary revenue year-over- South San Francisco year growth ~600 >170 >1,600
Slide 18: Global Presence with Significant Scale
Global Presence with Significant Scale Presence in 9 of Top 10 Pharma (WW) and 61% of Comprehensive Cancer Centers (US) Significant Global Scale • Research and Manufacturing capabilities in the United States, Canada and Singapore • Direct salesforce in the United States and Canada, with hybrid direc
Slide 19: Fluidigm Microfluidics Platform
Fluidigm Microfluidics Platform Offers ease of workflow, cost savings and turnaround time without sacrificing performance Sample-to-Answer IFC and Biomark™ X Microfluidics Integrated IFC loading and qPCR function (no more Juno™ ✓ or Controller) ✓ User installable 6x less volume (dimension) with same
Slide 20: Fluidigm Mass Cytometry Platform
Fluidigm Mass Cytometry Platform Offers ease of workflow, cost savings and turnaround time without sacrificing performance for both Suspension and Tissue Imaging CyTOF® XT The most technologically advanced mass cytometer to date, designed to Panels & build on the benefits of CyTOF® Instruments Reage
Slide 21: Fluidigm Mass Cytometry Platform: Hyperion Imaging System
Fluidigm Mass Cytometry Platform Offers ease of workflow, cost savings and turnaround time without sacrificing performance for both Suspension and Tissue Imaging Hyperion™ Imaging System • Exclusive high parameter spatial proteomics analysis platform using proven CyTOF® technology capable of Panels